Professor of Medical Oncology, Emory University
Oncology
Dr. Fadlo R. Khuri, MD
|
|
Give Review
Fadlo R. Khuri practices Oncology. He went to medical school at Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is a top medical university. Columbia University College of Physicians & Surgeons is ranked 8 in research and 52 in primary care medicine He received awards:"America's Top Doctors", "Atlanta Magazine: Top Doctors", "America's Top Doctors for Cancer", "Elected Member" and "Super Doctor". Fadlo R. Khuri, MD is also published. He has 101 publications published. The lastest publication: "Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal...' He is registered with Medicare and accepts Medicare payments.
Publications
- Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal...
- Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
- Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in Cancer cells.
- 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
- Enabling Systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform.
- Suppression of death receptor 5 enhances Cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling.
- The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
- LKB1 promotes Cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions.
- Predictors and outcomes of venous thromboembolism in hospitalized lung Cancer patients: A Nationwide Inpatient Sample database analysis.
- Time to divest from tobacco-funded research.
- Atypical carcinoid tumor of the Lung: a surveillance, epidemiology, and end results database analysis.
- GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress Cancer cell growth.
- Re-expression of LKB1 in LKB1-mutant EKVX Cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
- Anaplastic Lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.
- A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
- Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth.
- Cables1 complex couples survival signaling to the Cell death machinery.
- The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung Cancer.
- Development and testing of a tool to assess patient preferences for phase I clinical trial participation.
- Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic Squamous cell carcinoma of the head and neck.
- Post-Operative Radiotherapy (PORT) is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the Nationa...
- Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a Systematic review.
- Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the warburg effect.
- Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth.
- Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3.
- Second-Generation ALK Inhibitors: Filling the Non "MET" Gap.
- Using multiplexed assays of oncogenic drivers in lung Cancers to select targeted drugs.
- Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs.
- Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (HNSCC).
- Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis.
- Maintaining Glycogen Synthase Kinase-3 Activity Is Critical for mTOR Kinase Inhibitors to Inhibit Cancer Cell Growth.
- Class I HDACs Are Mediators of Smoke Carcinogen-Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer.
- Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck Cancer.
- Synthetic Curcumin Analog UBS Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts.
- Chemoprevention of head and neck Cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
- Escalation with overdose control using all toxicities and time to event toxicity data in Cancer Phase I clinical trials.
- A phase 2 trial of dacomitinib (PF-00299804), an Oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cel...
- Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex.
- HPV-associated lung Cancers: an international pooled analysis.
- Targeted therapies in metastatic esophageal Cancer: Advances over the past decade.
- Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.
- The Prometastatic Ribosomal S6 Kinase 2-cAMP Response Element-binding Protein (RSK2-CREB) Signaling Pathway Up-regulates the Actin-binding Protein Fascin-1 to Promote ...
- Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma.
- Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer.
- Pain Intensity and Pain Interference in Patients With Lung Cancer: A Pilot Study of Biopsychosocial Predictors.
- Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-Small Cell Lung Cancer.
- Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small-Cell Lung Cancer:...
- Targeting protein-protein interactions as an antiCancer strategy.
- A time-resolved fluorescence resonance energy transfer assay for high-throughput screening of 14-3-3 protein-protein interaction inhibitors.
- Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck.
- Paranasal sinus Squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results Data, 1973 to 2009.
- Correlates of continued smoking versus cessation among survivors of smoking-related Cancers.
- The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
- p90RSK2 mediates anti-anoikis signals by both transcription-dependent and -independent mechanisms.
- Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer.
- CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC.
- On collegiality and role models.
- mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis.
- Risk Factors for Rising Incidence of Esophageal and Gastric Cardia Adenocarcinoma.
- Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and n...
- A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor Malignancies.
- Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid Cancer.
- Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck s...
- c-Myc suppression of DNA double-strand break repair.
- Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
- The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung Cancer in vitro and in vivo.
- Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention.
- A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung Cancer.
- Synthetic curcumin analog EF31 inhibits the growth of head and neck Squamous cell carcinoma xenografts.
- Laryngeal tumor volume as a predictor for Thyroid cartilage penetration.
- Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung Cancer.
- Expression of concern.
- Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for Cancer metabolism.
- Why Cancer matters.
- NNK promotes migration and invasion of lung Cancer cells through activation of c-Src/ PKC?/ FAK loop.
- Oncogenic Ras and B-Raf positively regulates death receptor 5 expression through co-activation of ERK and JNK signaling.
- Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells.
- Advances in the management of recurrent or metastatic Squamous cell carcinoma of the head and neck.
- Tyrosine phosphorylation of LDH-A is important for NADH/NAD+ redox homeostasis in Cancer cells.
- Pleiotropic functions of EAPII/TTRAP/TDP2: Cancer development, chemoresistance and beyond.
- 14-3-3 proteins as potential therapeutic targets.
- Augmentation of NVP-BEZ235's antiCancer activity against human lung Cancer cells by blockage of autophagy.
- The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck Cancer cells.
- Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor.
- Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.
- The dawn of a revolution in personalized lung Cancer prevention.
- Human immunodeficiency virus-associated lung Cancer in the era of highly active antiretroviral therapy.
- Retinoic acid enhances TRAIL induced apoptosis in Cancer cells by upregulating TRAIL receptor 1 expression.
- The BATTLE Trial: Personalizing Therapy for Lung Cancer.
- Lung Cancer: New biological insights and recent therapeutic advances.
- Detection of circulating tumor Cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles.
- Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced Malignancies.
- Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck Cancer patients.
- The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic AntiCancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo.
- ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1.
- Lung Cancer in the elderly: what's age got to do with it?
- Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53.
- Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell Lung c...
- Cancer prevention with natural compounds.
- Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
Schools
Columbia University College Of Physicians and Surgeons
Boston City Hospital
New England Med Center Hosps
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Atlanta Magazine: Top Doctors
- America's Top Doctors for Cancer
- Elected Member
- Super Doctor
Education
-
Tufts Medical Center -
Boston University Medical Center -
Columbia University College of Physicians & Surgeons
Hospital
-
Emory University Hospital -
Grady Memorial Hospital -
Emory University Hospital Midtown
Drug Facts
| NPI NUMBER | 1366559023 | |
| NPPES Provider LastName | KHURI | |
| NPPES Provider FirstName | FADLO | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 362.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 3.59 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1366559023 |
| Last Name Of The Provider | KHURI |
| First Name Of The Provider | FADLO |
| View All |
Similar Doctors
|
|
Dr. Pradeep C. Jolly, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Vasileios J. Assikis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amelia A. Langston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy M. Baer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Otis W. Brawley Jr., MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Suresh S. Ramalingam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel W. Dubovsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura L. Weakland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manila Gaddh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret K. Offermann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Divya Tiwari, MD
This Doctor is OpenDoctor Recommended.
|